Paolo Ghia, MD, PhD, details the final analysis of the phase 2 CAPTIVATE study evaluating frontline ibrutinib/venetoclax in patients with CLL.

Treatment with mosunetuzumab plus polatuzumab vedotin yielded high response rates and had a manageable safety profile in BTK inhibitor–exposed MCL.

Compelling evidence supports the need to update the 2001 definition and diagnosis of disseminated intravascular coagulation (DIC) to reflect our curre…

Claire Harrison, MD, FRCP, FRCPath, discusses research that may evolve the clinical use of JAK inhibitors and mutation-specific therapies in myelofibrosis.

The EMA’s CHMP has approved isatuximab in combination with VRd for transplant-ineligible patients with newly diagnosed multiple myeloma.

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, held in New Orleans, LA, from 10 - 13 December 2022, with a…

Glofitamab generated high response rates and durable remissions in R/R mantle cell lymphoma, including high-risk subgroups, with sustained MRD negativity.

Based on a hypothesis that post-mortem cellular (chiefly nuclear) changes in the white blood cells could reliably be correlated with the time interval since death, (ti), serial observations were made ...